1. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
- Author
-
Renaud, Loïc, Bossard, Jean Baptiste, Carpentier, Benjamin, Terriou, Louis, Cambier, Nathalie, Chanteau, Guillaume, Escure, Guillaume, Tilmont, Remi, Barbieux, Sarah, Wemeau, Mathieu, Hieulle, Julia, Boyle, Eileen M., and Morschhauser, Franck
- Subjects
TEMOZOLOMIDE ,HIP fractures ,DIFFUSE large B-cell lymphomas ,FEBRILE neutropenia ,MAGNETIC resonance imaging ,TUMOR grading ,FECAL microbiota transplantation - Abstract
The patients in our study were nonetheless older, had worse performance status, a poor Charlson Comorbidity Index and were for most of them refractory to their previous treatment line thus explaining part of the lower ORR and CR rates in our cohort. Efficacy Patients received a median of 3.2 cycles (1-19 cycles), Figure 1A. One patient received whole brain radiotherapy consolidation after obtaining a partial response under treatment. All patients had relapsed (n = 6) or refractory (n = 16) disease, after a median of two lines of therapy (range, 1-3). [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF